Published in Carcinogenesis on October 01, 1995
Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics (1988) 2.26
Risk from low-dose exposures. Science (1994) 1.99
Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Toxicol Appl Pharmacol (1997) 1.75
Human exposure estimates for phthalates. Environ Health Perspect (2000) 1.53
Characterization of the dose-response of CYP1B1, CYP1A1, and CYP1A2 in the liver of female Sprague-Dawley rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol (1999) 1.43
Age-specific models of mortality and tumor onset for historical control animals in the National Toxicology Program's carcinogenicity experiments. Cancer Res (1986) 1.18
Temperature and air pollution as risk factors for heat stroke in Tokyo, July and August 1980-1995. Environ Health Perspect (1999) 1.18
Effects of temperature and air pollutants on cardiovascular and respiratory diseases for males and females older than 65 years of age in Tokyo, July and August 1980-1995. Environ Health Perspect (2001) 1.08
Receptor mechanisms and dose-response models for the effects of dioxins. Environ Health Perspect (1993) 1.06
Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver. Cancer Res (1992) 1.02
The application of a multistage model that incorporates DNA damage and repair to the analysis of initiation/promotion experiments. Math Biosci (1991) 1.00
Birth and death/differentiation rates of papillomas in mouse skin. Carcinogenesis (1992) 0.99
Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis. Environ Health Perspect (1996) 0.96
Effects of the mechanism of receptor-mediated gene expression on the shape of the dose-response curve. Risk Anal (1993) 0.95
A mechanistic model of effects of dioxin on gene expression in the rat liver. Toxicol Appl Pharmacol (1993) 0.95
Design of animal carcinogenicity studies for goodness-of-fit of multistage models. Fundam Appl Toxicol (1984) 0.95
The exact formula for tumor incidence in the two-stage model. Risk Anal (1994) 0.95
Workshop overview. National Toxicology Program Studies: principles of dose selection and applications to mechanistic based risk assessment. Fundam Appl Toxicol (1996) 0.93
Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. Toxicol Appl Pharmacol (1997) 0.92
A measure of tumorigenic potency incorporating dose-response shape. Biometrics (1993) 0.90
A mechanistic model of effects of dioxin on thyroid hormones in the rat. Toxicol Appl Pharmacol (1996) 0.89
Characterizing dose-response: I: Critical assessment of the benchmark dose concept. Risk Anal (1998) 0.89
Nonlinearity of dose-response functions for carcinogenicity. Environ Health Perspect (1994) 0.88
Identification of a cardiac sodium channel insensitive to synthetic modulators. J Cardiovasc Pharmacol Ther (2001) 0.86
Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. II. Rates of metabolism. Toxicol Appl Pharmacol (1998) 0.85
Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion. Toxicol Appl Pharmacol (2006) 0.85
Induction of lung lesions in female rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Pathol (2000) 0.85
Physiological modeling of a proposed mechanism of enzyme induction by TCDD. Toxicology (2001) 0.84
Cell proliferation and chemical carcinogenesis: symposium overview. Environ Health Perspect (1993) 0.84
Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans. Toxicol Appl Pharmacol (1999) 0.84
Cell proliferation and chemical carcinogenesis: a symposium overview. Mol Carcinog (1993) 0.83
An illustration of dangers of ignoring survival differences in carcinogenic data. J Appl Toxicol (1988) 0.83
Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration. Toxicol Appl Pharmacol (2004) 0.82
Reevaluating cancer risk estimates for short-term exposure scenarios. Toxicol Sci (2000) 0.81
A physiologically based pharmacokinetic model for inhalation and intravenous administration of naphthalene in rats and mice. Toxicol Appl Pharmacol (2001) 0.81
Semiparametric analysis of tumor incidence rates in survival/sacrifice experiments. Biometrics (1987) 0.81
Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice. Drug Metab Dispos (1998) 0.81
Multiple organ carcinogenicity of inhaled chloroprene (2-chloro-1,3-butadiene) in F344/N rats and B6C3F1 mice and comparison of dose-response with 1,3-butadiene in mice. Carcinogenesis (1999) 0.81
Distinguishing between models of carcinogenesis: the role of clonal expansion. Fundam Appl Toxicol (1991) 0.80
Quantitative mechanistically based dose-response modeling with endocrine-active compounds. Environ Health Perspect (1999) 0.79
Replication potential of cells via the protein kinase C-MAPK pathway: application of a mathematical model. Bull Math Biol (1999) 0.79
Should the presence of carcinogens in breast milk discourage breast feeding? Regul Toxicol Pharmacol (1991) 0.79
The two-stage model of carcinogenesis: overcoming the nonidentifiability dilemma. Risk Anal (1997) 0.79
Stochastic simulation of a multistage model of carcinogenesis. Math Biosci (1996) 0.78
A note on fitting one-compartment models: non-linear least squares versus linear least squares using transformed data. J Appl Toxicol (1990) 0.78
Effects of ketanserin and DOI on spontaneous and 5-HT-evoked peristalsis of the pig ureter in vivo. Br J Pharmacol (2002) 0.77
Incorporating observability thresholds of tumors into the two-stage carcinogenesis model. Math Biosci (2000) 0.77
A mathematical model of production, distribution, and metabolism of melatonin in mammalian systems. Toxicol Appl Pharmacol (1997) 0.77
In vitro effects of bethanechol on smooth muscle preparations from abomasal fundus, corpus, and antrum of dairy cows. Res Vet Sci (2007) 0.77
A note on approximating the cumulative distribution function of the time to tumor onset in multistage models. Biometrics (1989) 0.77
Hepatocarcinogenesis in female Sprague-Dawley rats following discontinuous treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci (2000) 0.77
Calculation of the cumulative distribution function of the time to a small observable tumor. Bull Math Biol (2000) 0.77
A physiologically based pharmacokinetic model of p,p'-dichlorodiphenylsulfone. Toxicol Appl Pharmacol (2002) 0.76
A stem cell model for carcinogenesis. Math Biosci (1994) 0.76
The importance of biological realism in dioxin risk assessment models. Risk Anal (1994) 0.76
Concordance of carcinogenic response between rodent species: potency dependence and potential underestimation. Risk Anal (1992) 0.75
Stereoselective biotransformation of ketamine in equine liver and lung microsomes. J Vet Pharmacol Ther (2008) 0.75
Eyes closed: simple, intuitive, statistically sound, and efficient methods for estimating parameters of clonal growth cancer models. Risk Anal (1998) 0.75
Type 1 error and power of the linear trend test in proportions under the National Toxicology Program's modified pathology protocol. Fundam Appl Toxicol (1986) 0.75
Carcinoma formation in NMRI mouse skin painting studies is a process suggesting greater than two stages. Carcinogenesis (1995) 0.75
An index of tumorigenic potency. Biometrics (1993) 0.75
An evaluation of some methods for fitting dose-response models to quantal-response developmental toxicology data. Biometrics (1993) 0.75
A model of effects of TCDD on expression of rat liver proteins. Prog Clin Biol Res (1994) 0.75
An evaluation of the Rai and Van Ryzin dose-response model in teratology. Risk Anal (1991) 0.75
The use of data on biologically reactive intermediates in risk assessment. Adv Exp Med Biol (1996) 0.75
Multistage models of carcinogenesis: an approximation for the size and number distribution of late-stage clones. Risk Anal (1994) 0.75
Practicing safe modeling: GLP for biologically based mechanistic models. Environ Health Perspect (1996) 0.75